Innovative Life Sciences Corporation (ILS) was founded in January 2006 by a group of professionals who wanted to address the need for an alternative treatment of cardiovascular conditions other than prescription drugs.The Company developed a proprietary nutraceutical product as a core technology to aid in treating cardiovascular conditions. ILS has isolated the active ingredient in Cinnamon Cassia and has scientifically enhanced its concentration by 12 times to create a unique and powerful natural extract called CM-X®.
Governor General's Medal 1971
Prior to joining ILS, he built a design based empire, sold to Reebok (now Adidas Group of Companies) in 2003. His expertise includes astute financial and operations management, exceptional marketing and promotional skill, and a unique celebrity network to benefit the strategic plan of ILS.
Roger is the major creative force for ensuring the integrity, value and consumer appeal of ILS products, as well as the central and driving force in ensuring shareholder value. Roger is a major shareholder of ILS.
Shiela D. Collin D. Jur.
She also sits on corporate boards in areas as diverse as high tech metal coatings, cosmetic manufacturing and distribution, property management, and international charities.
Sheila is a founder and principal of Professional Artists (Canada) Inc., the innovator of the BeautySoClean line, which is marketed to the public in North America, and available through distributors to salons, spas and professional makeup artists internationally.
Sheila holds a Doctor of Laws degree from Osgoode Hall Law School. She is also a trained mediator and arbitrator.Her current community activities include serving as Vice President for both ORT Canada and ORT Toronto, consulting as a member of the international allocations committee for World ORT, and working with local philanthropists to create and implement charitable projects benefiting her community.
Sheila began as an investor and director of Innovate Life Sciences Corporation in 2006. Since that time, she has worked regularly with management, to promote and assist in the growth of the company.
B.Sc. PHM., R.PH., LL.B., J.D., Ph.D.
Dr. Herbert attended law school at Queen’s University and graduated with a Bachelor of Laws (LL.B) and a Juris Doctor (JD) from Queen’s in 1972. He joined Riches, McKenzie & Herbert LLP as an articling student and was called to the bar in the province of Ontario in 1974. He became a partner in the firm in 1975 and is now the senior partner. Dr. Herbert was awarded his Ph.D. in law in 2008.
Dr. Herbert qualified as a Canadian patent and trade mark agent in 1974 and is also licensed to practice before the United States Patent Office.
Dr. Herbert has been active in many professional organizations during his career. A few of these include being president of the Product Development and Management Association of Canada from 1998 to 2000 and chairman of the Toronto Patent and Trademark Group from 1978 to 1980. He was a member of the Board of Trade of Metropolitan Toronto and vice-chairman of its Committee on Patents, Trade Marks, Industrial Designs and Copyrights from 1989 to 1997. He was elected chairman of the Committee on Patents, Trade Marks, Industrial Designs and Copyrights of the Board of Trade Metropolitan Toronto from 1997 to 2003. Dr. Herbert was a member of the Board of Directors and Executive Committee of the Innovations Foundation of the University of Toronto from 1988 to 1997 and was elected Chairman of the Foundation from 1993 to 1997.
Dr. Herbert is a member in good standing of the Canadian Bar Association, the American Bar Association, the Law Society of Upper Canada, the Canadian Pharmaceutical Association, the Ontario College of Pharmacists, the Ontario Pharmacists Association and the Metropolitan Toronto Retail Pharmacists Association. He is a member of the International Association for the Protection of Industrial Property, a fellow of the Intellectual Property Institute of Canada and a member of the Fédération Internationale Des Conseils En Propriété Industrielle (FICPI).
She assess the efficacy and safety of nutraceutically-based treatments for many of the so-called “lifestyle” diseases and conditions of the industrialized world by using clinical trial expertise. She evaluates unique properties of naturally-occurring foods, plants and herbs in novel products targeted to the marketplace.
Dr. Laidlaw conducts clinical trials under strict regulations from the Natural Health Products Directorate of Health Canada, and is familiar with the intricacies and regulatory framework involved in human drug trials.